Wedbush Maintains Outperform on AnaptysBio, Raises Price Target to $75
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Martin Fan maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $60 to $75.
Wedbush analyst Martin Fan maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $60 to $75.